A
Allan I. Levey
Researcher at Emory University
Publications - 508
Citations - 69800
Allan I. Levey is an academic researcher from Emory University. The author has contributed to research in topics: Medicine & Alzheimer's disease. The author has an hindex of 123, co-authored 445 publications receiving 62087 citations. Previous affiliations of Allan I. Levey include University of Washington & Boston University.
Papers
More filters
Journal ArticleDOI
Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6).
TL;DR: It appears that the age-related changes of memory function as well as some of the behavioral disturbances seen in the dementia of Alzheimer's Disease may be related to pathological alterations along central cholinergic pathways.
Journal ArticleDOI
Variant of TREM2 associated with the risk of Alzheimer's disease
Thorlakur Jonsson,Hreinn Stefansson,Stacy Steinberg,Ingileif Jonsdottir,Palmi V. Jonsson,Jon Snaedal,Sigurbjorn Bjornsson,Johanna Huttenlocher,Allan I. Levey,James J. Lah,Dan Rujescu,Harald Hampel,Ina Giegling,Ole A. Andreassen,Knut Engedal,Ingun Ulstein,Srdjan Djurovic,Carla A. Ibrahim-Verbaas,Albert Hofman,M. Arfan Ikram,Cornelia M. van Duijn,Unnur Thorsteinsdottir,Augustine Kong,Kari Stefansson +23 more
TL;DR: These findings strongly implicate variant TREM2 in the pathogenesis of Alzheimer's disease and find that carriers of rs75932628-T between the ages of 80 and 100 years without Alzheimer’s disease had poorer cognitive function than noncarriers.
Journal ArticleDOI
Cholinergic innervation of cortex by the basal forebrain : cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey
TL;DR: The organization of projections from the cholinergic neurons of the basal forebrain to neocortex and associated structures was investigated in the rhesus monkey with the help of horseradish peroxidase transport, acetyl‐cholinesterase histochemistry, and choline acetyltransferase immunohis‐tochemistry.
Journal ArticleDOI
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.
Adam C. Naj,Gyungah Jun,Gary W. Beecham,Li-San Wang,Badri N. Vardarajan,Jacqueline L. Buros,Paul Gallins,Joseph D. Buxbaum,Gail P. Jarvik,Paul K. Crane,Eric B. Larson,Thomas D. Bird,Bradley F. Boeve,Neill R. Graff-Radford,Philip L. De Jager,Philip L. De Jager,Denis A. Evans,Julie A. Schneider,Minerva M. Carrasquillo,Nilufer Ertekin-Taner,Steven G. Younkin,Carlos Cruchaga,John S. K. Kauwe,Petra Nowotny,Patricia L. Kramer,John Hardy,Matthew J. Huentelman,Amanda J. Myers,M. Michael Barmada,F. Yesim Demirci,Clinton T. Baldwin,Robert C. Green,Ekaterina Rogaeva,Peter St George-Hyslop,Peter St George-Hyslop,Steven E. Arnold,Robert W Barber,Thomas H. Beach,Eileen H. Bigio,James D. Bowen,Adam L. Boxer,James R. Burke,Nigel J. Cairns,Christopher S. Carlson,Regina M. Carney,Steven L. Carroll,Helena C. Chui,David G. Clark,Jason J. Corneveaux,Carl W. Cotman,Jeffrey L. Cummings,Charles DeCarli,Steven T. DeKosky,Ramon Diaz-Arrastia,Malcolm B. Dick,Dennis W. Dickson,William G. Ellis,Kelley Faber,Kenneth B. Fallon,Martin R. Farlow,Steven H. Ferris,Matthew P. Frosch,Douglas Galasko,Mary Ganguli,Marla Gearing,Daniel H. Geschwind,Bernardino Ghetti,John R. Gilbert,Sid Gilman,Bruno Giordani,Jonathan D. Glass,John H. Growdon,Ronald L. Hamilton,Lindy E. Harrell,Elizabeth Head,Lawrence S. Honig,Christine M. Hulette,Bradley T. Hyman,Gregory A. Jicha,Lee-Way Jin,Nancy Johnson,Jason Karlawish,Anna Karydas,Jeffrey Kaye,Ronald C. Kim,Edward H. Koo,Neil W. Kowall,James J. Lah,Allan I. Levey,Andrew P. Lieberman,Oscar L. Lopez,Wendy J. Mack,Daniel C. Marson,Frank Martiniuk,Deborah C. Mash,Eliezer Masliah,Wayne C. McCormick,Susan M. McCurry,Andrew McDavid,Ann C. McKee,W Marsel Mesulam,Bruce L. Miller,Carol A. Miller,Joshua W. Miller,Joseph E. Parisi,Daniel P. Perl,Elaine R. Peskind,Ronald C. Petersen,Wayne W. Poon,Joseph F. Quinn,Ruchita Rajbhandary,Murray A. Raskind,Barry Reisberg,John M. Ringman,Erik D. Roberson,Roger N. Rosenberg,Mary Sano,Lon S. Schneider,William P. Seeley,Michael L. Shelanski,Michael A. Slifer,Charles D. Smith,Joshua A. Sonnen,Salvatore Spina,Robert S. Stern,Rudolph E. Tanzi,John Q. Trojanowski,Juan C. Troncoso,Vivianna M. Van Deerlin,Harry V. Vinters,Jean Paul Vonsattel,Sandra Weintraub,Kathleen A. Welsh-Bohmer,Jennifer Williamson,Randall L. Woltjer,Laura B. Cantwell,Beth A. Dombroski,Duane Beekly,Kathryn L. Lunetta,Eden R. Martin,M. Ilyas Kamboh,Andrew J. Saykin,Eric M. Reiman,David A. Bennett,John C. Morris,Thomas J. Montine,Alison Goate,Deborah Blacker,Debby W. Tsuang,Hakon Hakonarson,Walter A. Kukull,Tatiana Foroud,Jonathan L. Haines,Richard Mayeux,Margaret A. Pericak-Vance,Lindsay A. Farrer,Gerard D. Schellenberg +156 more
TL;DR: The Alzheimer Disease Genetics Consortium performed a genome-wide association study of late-onset Alzheimer disease using a three-stage design consisting of a discovery stage (stage 1), two replication stages (stages 2 and 3), and both joint analysis and meta-analysis approaches were used.
Journal ArticleDOI
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Ronald C. Petersen,Ronald G. Thomas,Michael Grundman,David A. Bennett,Rachelle S. Doody,Steven H. Ferris,Douglas Galasko,Shelia Jin,Jeffrey Kaye,Allan I. Levey,Eric Pfeiffer,Mary Sano,Christopher H. van Dyck,Leon J. Thal +13 more
TL;DR: Vitamin E had no benefit in patients with mild cognitive impairment and donepezil therapy was associated with a lower rate of progression to Alzheimer's disease during the first 12 months of treatment, a finding supported by the secondary outcome measures.